Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results

Mehmet Hilmi Dogu¹, Ali Irfan Emre Tekgunduz², Burak Deveci³, Gulten Korkmaz⁴, Melda Comert⁵, Omur Gokmen Sevindik⁶, Osman Yokus⁷ and İstemi Serin⁷.

¹ Department of Hematology, Istinye University, Faculty of Medicine, Liv Hospital Ulus, Istanbul, Turkey.
² Department of Hematology, Istanbul Memorial Bahcelievler, Istanbul, Turkey.
³ Department of Hematology, Medstar Antalya Hospital, Antalya, Turkey.
⁴ Department of Hematology, Ankara City Hospital, Turkey.
⁵ Department of Hematology, University of Health Sciences, Gulhane Training and Research Hospital, Istanbul, Turkey.
⁶ Department of Hematology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkey.
⁷ Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.

**Supplementary Tables**

**Supplementary Table 1.** Side effects with gilteritinib response status

<table>
<thead>
<tr>
<th>Gilteritinib response (Presence of progression)</th>
<th>Total (n=17)</th>
<th>No (n=11)</th>
<th>Yes (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>13 (76.5)</td>
<td>9 (81.8)</td>
<td>4 (66.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>4 (23.5)</td>
<td>2 (18.2)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>Anemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>10 (58.8)</td>
<td>6 (54.5)</td>
<td>4 (66.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>7 (41.2)</td>
<td>5 (45.5)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>Transaminase increase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>12 (70.6)</td>
<td>7 (63.6)</td>
<td>5 (83.3)</td>
</tr>
<tr>
<td>Yes</td>
<td>5 (29.4)</td>
<td>4 (36.4)</td>
<td>1 (16.7)</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>16 (94.1)</td>
<td>10 (90.9)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Yes</td>
<td>1 (5.9)</td>
<td>1 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>16 (94.1)</td>
<td>10 (90.9)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Yes</td>
<td>1 (5.9)</td>
<td>1 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>10 (58.8)</td>
<td>6 (54.5)</td>
<td>4 (66.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>7 (41.2)</td>
<td>5 (45.5)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>ALP Increase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>15 (88.2)</td>
<td>9 (81.8)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Yes</td>
<td>2 (11.8)</td>
<td>2 (18.2)</td>
<td>-</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>11 (64.7)</td>
<td>7 (63.6)</td>
<td>4 (66.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>6 (35.3)</td>
<td>4 (36.4)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>16 (94.1)</td>
<td>10 (90.9)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Yes</td>
<td>1 (5.9)</td>
<td>1 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>Condition</td>
<td>No</td>
<td>Yes</td>
<td>( \chi^2 )</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------</td>
<td>-------</td>
<td>--------------</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>16 (94.1)</td>
<td>1 (5.9)</td>
<td>0.35</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>13 (76.5)</td>
<td>4 (23.5)</td>
<td>0.58</td>
</tr>
<tr>
<td>Headache</td>
<td>16 (94.1)</td>
<td>1 (5.9)</td>
<td>0.35</td>
</tr>
<tr>
<td>Cardiac</td>
<td>16 (94.1)</td>
<td>1 (5.9)</td>
<td>0.99</td>
</tr>
<tr>
<td>Hypomagnesaemia</td>
<td>15 (88.2)</td>
<td>2 (11.8)</td>
<td>0.99</td>
</tr>
</tbody>
</table>

**ALP:** Alkaline phosphatase  
*(p<0.05 significance) Student's t|Mann‒Whitney U test, Chi-Square|Exact test*
**Supplementary Table 2.** Comparison of survival curves (log-rank test) and hazard ratios with 95% confidence intervals

<table>
<thead>
<tr>
<th></th>
<th>Non-Progressive n (%)</th>
<th>Progressive n (%)</th>
<th>Median/Mean Survival (95% CI)</th>
<th>Hazard Ratio (95% CI)</th>
<th>Log Rank p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>4 (100)</td>
<td>0 (0)</td>
<td>813 (813-813)</td>
<td>-</td>
<td>0.11</td>
</tr>
<tr>
<td>Female</td>
<td>7 (53.85)</td>
<td>6 (46.15)</td>
<td>487 (285.7-690.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Risk classification by genetics at initial diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>8 (61.54)</td>
<td>5 (38.46)</td>
<td>514 (313.9-714.9)</td>
<td>1.87 (0.31-11.39)</td>
<td>0.49</td>
</tr>
<tr>
<td>Adverse</td>
<td>3 (75)</td>
<td>1 (25)</td>
<td>762 (762-762)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Presence of mutations other than FLT3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4 (57.14)</td>
<td>3 (42.86)</td>
<td>562.3 (275.5-849.1)</td>
<td>1.49 (0.28-7.84)</td>
<td>0.64</td>
</tr>
<tr>
<td>No</td>
<td>7 (70)</td>
<td>3 (30)</td>
<td>583.8 (372.1-795.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number of previous treatment steps</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>7 (58.33)</td>
<td>5 (41.67)</td>
<td>552.2 (363.6-740.8)</td>
<td>1.3 (0.15-10.95)</td>
<td>0.81</td>
</tr>
<tr>
<td>3-5</td>
<td>4 (80)</td>
<td>1 (20)</td>
<td>167.6 (110.8-224.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Allogeneic transplantation in previous treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2 (100)</td>
<td>0 (0)</td>
<td>200 (200-200)</td>
<td>-</td>
<td>0.44</td>
</tr>
<tr>
<td>No</td>
<td>9 (60)</td>
<td>6 (40)</td>
<td>540 (365.1-715.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Induction therapy response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>5 (55.56)</td>
<td>4 (44.4)</td>
<td>552.9 (267.4-778.4)</td>
<td>2.52 (0.48-13.17)</td>
<td>0.27</td>
</tr>
<tr>
<td>Yes</td>
<td>6 (75)</td>
<td>2 (25)</td>
<td>638.3 (432.8-843.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pre-gilteritinib FLT3 exposure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6 (75)</td>
<td>2 (25)</td>
<td>299.3 (204.3-394.2)</td>
<td>1.01 (0.14-7.01)</td>
<td>0.99</td>
</tr>
<tr>
<td>No</td>
<td>5 (55.56)</td>
<td>4 (44.44)</td>
<td>566.2 (355.1-777.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Post-transplant gilteritinib maintenance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>9 (60)</td>
<td>6 (40)</td>
<td>508.2 (315.3-701.1)</td>
<td>-</td>
<td>0.27</td>
</tr>
<tr>
<td>Yes</td>
<td>2 (100)</td>
<td>0 (0)</td>
<td>716 (716-716)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Febrile neutropenia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2 (50)</td>
<td>2 (50)</td>
<td>88 (31-88)</td>
<td>4.86 (0.47-50.96)</td>
<td>0.19</td>
</tr>
<tr>
<td>No</td>
<td>9 (69.23)</td>
<td>4 (30.77)</td>
<td>762 (457-762)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (71.43)</td>
<td>2 (28.57)</td>
<td>528.4 (308.4-748.4)</td>
<td>1.13 (0.18-7.02)</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>4 (40)</td>
<td>569.2 (365.9-772.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>----------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transaminase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase</td>
<td>No</td>
<td>7 (58.33)</td>
<td>579 (338.8-819.2)</td>
<td>1.69 (0.25-11.34)</td>
<td>0.59</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>4 (80)</td>
<td>519.8 (315.5-724.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>No</td>
<td>6 (60)</td>
<td>458.6 (218.1-699.1)</td>
<td>1.7 (0.34-8.6)</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>5 (71.43)</td>
<td>657.6 (389.6-925.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>Yes</td>
<td>2 (50)</td>
<td>88 (31-88)</td>
<td>4.86 (0.46-50.96)</td>
<td>0.19</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>9 (69.23)</td>
<td>762 (457-762)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last status</td>
<td>Ex</td>
<td>6 (60)</td>
<td>137.2 (88.3-186.1)</td>
<td>6.29 (0.87-45.25)</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>Alive</td>
<td>5 (71.43)</td>
<td>721.4 (602.1-840.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FLT3**: FMS-like tyrosine kinase 3
**Supplementary Table 3.** Comparison of survival curves (log-rank test) and hazard ratios with 95% confidence intervals

<table>
<thead>
<tr>
<th></th>
<th>EX n (%)</th>
<th>Non-EX n (%)</th>
<th>Median/Mean Survival (95% CI)</th>
<th>Hazard Ratio (95% CI)</th>
<th>Log Rank p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>3 (75)</td>
<td>1 (25)</td>
<td>117 (106-117)</td>
<td>1.61 (0.35-7.45)</td>
<td>0.54</td>
</tr>
<tr>
<td>Female</td>
<td>7 (53.85)</td>
<td>6 (46.15)</td>
<td>200 (88-200)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Risk classification by genetics at initial diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>8 (61.54)</td>
<td>5 (38.46)</td>
<td>129 (88-149)</td>
<td>1.72 (0.45-6.68)</td>
<td>0.44</td>
</tr>
<tr>
<td>Adverse</td>
<td>2 (50)</td>
<td>2 (50)</td>
<td>200 (117-200)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Presence of mutations other than FLT3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6 (85.71)</td>
<td>1 (14.29)</td>
<td><strong>226.1 (20.3-431.9)</strong></td>
<td>3.23 (0.85-12.32)</td>
<td>0.09</td>
</tr>
<tr>
<td>No</td>
<td>4 (40)</td>
<td>6 (60)</td>
<td><strong>514.5 (288.3-740.6)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number of previous treatment steps</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-5</td>
<td>6 (50)</td>
<td>6 (50)</td>
<td>149 (31-149)</td>
<td>1.83 (0.45-7.46)</td>
<td>0.41</td>
</tr>
<tr>
<td>1-2</td>
<td>4 (80)</td>
<td>1 (20)</td>
<td>129 (89-200)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Allogeneic transplantation in previous treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1 (50)</td>
<td>1 (50)</td>
<td>200</td>
<td>1.47 (0.25-8.64)</td>
<td>0.67</td>
</tr>
<tr>
<td>No</td>
<td>9 (60)</td>
<td>6 (40)</td>
<td>129 (88-149)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Induction therapy response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>7 (77.78)</td>
<td>2 (22.22)</td>
<td><strong>112.2 (62.8-502.7)</strong></td>
<td>2.45 (0.7-8.58)</td>
<td>0.16</td>
</tr>
<tr>
<td>Yes</td>
<td>3 (37.5)</td>
<td>5 (62.5)</td>
<td><strong>547.1 (309.2-785.1)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pre-gilteritinib FLT3 exposure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6 (75)</td>
<td>2 (25)</td>
<td><strong>172.7 (98.6-246.7)</strong></td>
<td>1.91 (0.54-6.82)</td>
<td>0.32</td>
</tr>
<tr>
<td>No</td>
<td>4 (44.44)</td>
<td>5 (55.56)</td>
<td><strong>534.6 (263.2-805.8)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Post-transplant gilteritinib maintenance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0 (0)</td>
<td>2 (100)</td>
<td><strong>716</strong></td>
<td>-</td>
<td>0.14</td>
</tr>
<tr>
<td>No</td>
<td>10 (66.7)</td>
<td>5 (33.33)</td>
<td><strong>355.2 (160.9-549.6)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Febrile neutropenia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4 (100)</td>
<td>0 (0)</td>
<td><strong>96.25 (47.1-145.4)</strong></td>
<td>7.36 (1.26-43.05)</td>
<td><strong>0.03</strong></td>
</tr>
<tr>
<td>No</td>
<td>6 (46.5)</td>
<td>7 (53.85)</td>
<td><strong>530.5 (310.8-750.2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anemia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (71.43)</td>
<td>2 (28.57)</td>
<td>149 (31-200)</td>
<td>1.62 (0.45-5.86)</td>
<td>0.46</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----</td>
<td>------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Transaminase increase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>5 (50)</td>
<td>7 (58.33)</td>
<td>5 (41.67)</td>
<td>117 (88-129)</td>
<td>1.24 (0.33-4.67)</td>
</tr>
<tr>
<td>Yes</td>
<td>3 (60)</td>
<td>3 (60)</td>
<td>2 (40)</td>
<td>200 (31-200)</td>
<td></td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>7 (70)</td>
<td>3 (30)</td>
<td>310 (106.1-515.2)</td>
<td>2.24 (0.63-7.96)</td>
<td>0.21</td>
</tr>
<tr>
<td>Yes</td>
<td>3 (42.86)</td>
<td>4 (57.14)</td>
<td>529.7 (221.2-838.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral edema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4 (100)</td>
<td>0 (0)</td>
<td>93.5 (45.6-141.4)</td>
<td>10.47 (1.64-66.82)</td>
<td>0.01</td>
</tr>
<tr>
<td>No</td>
<td>6 (46.15)</td>
<td>7 (53.85)</td>
<td>531.3 (312.1-750.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FLT3: FMS-like tyrosine kinase 3